FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions

If you’ve been waiting for a GLP-1 that doesn’t involve needles, it’s here. The FDA approved Foundayo (orforglipron) on April 1, 2026, making it the first oral GLP-1 medication for weight loss that you can take at any time of day, with or without food, with or without water. No fasting windows. No 30-minute wait before eating. Just a daily pill.

That last part matters more than it sounds. The only other oral GLP-1, Rybelsus (oral semaglutide), requires you to take it on an empty stomach with no more than 4 ounces of water and wait at least 30 minutes before eating or drinking anything else. Many patients find that routine difficult to maintain, especially long-term. Foundayo has none of those restrictions, which should translate into better adherence for people who struggle with rigid dosing schedules.

The pricing is the other big story. Lilly set the self-pay price at $149/month, which makes Foundayo the cheapest branded GLP-1 medication on the market by a wide margin. For comparison, Wegovy lists above $1,300/month and Zepbound at $1,086 (though the KwikPen self-pay is $299 to $449). If you have commercial insurance, Lilly’s savings card can bring your copay down to $25/month. The $149 self-pay price puts brand-name GLP-1 therapy in range of what compounded versions cost through telehealth providers, which was clearly Lilly’s intent.

Where can you actually get it? Foundayo is available now at retail pharmacies, through LillyDirect for home delivery, through Ro as part of their weight management program, Amazon Pharmacy, and Weight Watchers Med+. Getting a prescription is the standard process: you need a BMI of 30 or above, or 27 or above with at least one weight-related condition. Telehealth providers like Hims, Found, and PlushCare can evaluate you and write a prescription, often within a day. Clinical trials showed average weight loss of 27.3 pounds at the highest dose, which is solid though somewhat below the 30+ pounds seen with injectable tirzepatide.

Source: Eli Lilly Press Releases

Frequently asked questions

How does Foundayo compare to injectable GLP-1 medications for weight loss?

Clinical trials showed average weight loss of 27.3 pounds (about 10-11% body weight) at the highest dose of Foundayo over 36 weeks. Injectable Wegovy averages about 15% body weight loss and Zepbound about 18-22%. So injectables still produce more weight loss on average. But Foundayo offers convenience (no needles, no fasting rules) and a much lower price point ($149/month vs $1,000+). For many patients, the tradeoff of slightly less weight loss for a simpler, cheaper daily pill will be worthwhile.

Can I switch from an injectable GLP-1 to Foundayo?

Yes, but talk to your prescriber first. The switch protocol depends on what you’re currently taking and your dose. If you’re on a low dose of semaglutide or tirzepatide and looking to reduce costs or avoid injections, Foundayo is a reasonable option. If you’re on a high dose of an injectable and losing weight successfully, switching to an oral medication with somewhat lower average efficacy is a risk-benefit conversation. Your provider can help you weigh the tradeoffs based on your specific situation.

Does insurance cover Foundayo?

Coverage is still rolling out. Lilly has been aggressive about getting Foundayo on formularies, and the $25/month copay card for commercially insured patients suggests they expect broad commercial coverage. Medicare and Medicaid coverage for weight-loss medications is more complicated and varies by state. If you have commercial insurance, check with your plan or ask your provider to run a benefits check. If you’re paying cash, the $149/month self-pay price is available without insurance through LillyDirect and retail pharmacies.

Keep reading

• Foundayo: Full medication profile
• Ro: Provider profile and pricing
• Foundayo vs Wegovy: Oral vs injectable
• GLP-1 eligibility quiz